Advertisement

Topics

Pixium Vision (PIX) - Key Iris II and Prima catalysts for H217

08:20 EDT 22 Aug 2017 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - Pixium Vision: Pixium is building up a sales channel across Europe for its Iris II device, and is working on securing reimbursement and generating initial product sales in H217. It is also planning to start first-in-human trials for the next-generation Prima implant in H217. Using a risk-adjusted NPV model, we obtain a pipeline rNPV of €129.3m, compared to €131.4m, previously.
ISIN: FR0011950641

Original Article: Pixium Vision (PIX) - Key Iris II and Prima catalysts for H217

NEXT ARTICLE

More From BioPortfolio on "Pixium Vision (PIX) - Key Iris II and Prima catalysts for H217"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...